BrainXell, a US biotechnology company developing iPSC-based CNS disease models and regenerative cell therapies, has announced ...

Chinese cell therapy developer NK CellTech has raised nearly 100 million renminbi ($14 million) in an extended series A+++ ...

Lewy body dementia (LBD) remains one of the most overlooked and complex neurodegenerative conditions, but momentum is ...

Sino-American biopharma Ascentage Pharma announced that its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575 ...

The US Food and Drug Administration (FDA) has approved US mRNA specialist Moderna supplemental Biologics License Application ...

Shares in US biotech Ultragenyx Pharmaceutical (Nasdaq: RARE) and its UK-based partner Mereo BioPharma (Nasdaq: MREO) tumbled ...

French biotech Osivax has published results from a Phase IIa trial showing that its lead candidate OVX836, a broad-spectrum ...

China-based biotech Biocytogen has signed a global licensing agreement with oncology-focused BeOne Medicines (SHA: 688235), ...

The US Food and Drug Administration (FDA) has taken the radical move of publishing more than 200 decision letters, known as ...

The US Food and Drug Administration (FDA) has accepted for review Merck & Co’s New Drug Application (NDA) for ...

US late-stage oncology-focused Revolution Medicines and Iambic Therapeutics, which is developing novel medicines using its AI ...

The European Commission has approved Tevimbra (tislelizumab), alongside gemcitabine and cisplatin, for the first-line ...